Olanzapine

Delirium, Delusional Parasitosis, Schizophrenia + 11 more

Treatment

8 FDA approvals

20 Active Studies for Olanzapine

What is Olanzapine

Olanzapine

The Generic name of this drug

Treatment Summary

Olanzapine is an atypical antipsychotic medication that was developed in the 1990s and is used to treat mental health conditions. This drug is similar to clozapine but has two additional methyl groups and does not contain a chloride moiety. Olanzapine was approved by the U.S. Food and Drug Administration in 1996 and is known for its effectiveness and reduced risk of side effects compared to other antipsychotic medications.

Zyprexa

is the brand name

image of different drug pills on a surface

Olanzapine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zyprexa

Olanzapine

1996

546

Approved as Treatment by the FDA

Olanzapine, otherwise known as Zyprexa, is approved by the FDA for 8 uses which include Mental Depression and Bipolar Disorder .

Mental Depression

Used to treat Acute Depressive Episode in combination with Fluoxetine

Bipolar Disorder

Used to treat Bipolar 1 Disorder in combination with Fluoxetine

Bipolar Disorder

Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation

Unipolar Depression

Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Bipolar Disorder With Manic or Mixed Episodes

Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation

Bipolar 1 Disorder

Used to treat Bipolar 1 Disorder in combination with Fluoxetine

Acute Depressive Episode

Used to treat Acute Depressive Episode in combination with Fluoxetine

Major depressive disorder, recurrent episode

Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Effectiveness

How Olanzapine Affects Patients

Olanzapine is used to reduce the symptoms of schizophrenia and bipolar disorder in adults, and manic or mixed episodes in adolescents. It works by targeting certain receptors in the brain like the dopamine D2 receptor and serotonin 5HT2A receptor. This helps to reduce hallucinations, delusions, disorganized speech, disorganized thought, disorganized behavior, anhedonia, flat affect, alogia, avolition and poor attention. Olanzapine may also be used to reduce chemotherapy-induced nausea and vomiting as it has been found to be effective in providing complete response on the delay phase in 84% of individuals and control of emesis

How Olanzapine works in the body

Olanzapine works by blocking several different types of receptors in the brain. It blocks dopamine receptors, serotonin receptors, adrenergic receptors, histamine receptors, and muscarinic receptors. Out of these, blocking the dopamine receptors in the mesolimbic pathway is the most important action. Olanzapine also blocks serotonin 5HT2A receptors in the frontal cortex, which reduces the severity of side effects.

When to interrupt dosage

The encouraged dosage of Olanzapine is contingent upon the identified condition, such as Schizophrenia, Bipolar Disorder and Delirium. The measure of dosage changes, in accordance with the method of delivery (e.g. Kit - Intramuscular or Tablet, film coated - Oral) noted in the table beneath.

Condition

Dosage

Administration

Delirium

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Post Traumatic Stress Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Tourette Syndrome

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Mental Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Acute Agitation

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Unipolar Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Acute Coryza

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Delusional Parasitosis

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Alzheimer's Disease

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular

Warnings

There are 20 known major drug interactions with Olanzapine.

Common Olanzapine Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Olanzapine.

Acepromazine

Major

Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Olanzapine is combined with Aclidinium.

Alfuzosin

Major

Olanzapine may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Olanzapine may increase the antipsychotic activities of Amisulpride.

Olanzapine Toxicity & Overdose Risk

Taking too much olanzapine can cause drowsiness, dilated pupils, difficulty breathing, low blood pressure, involuntary muscle movement, and other anticholinergic effects. In some cases, people have experienced agitation, slurred speech, rapid heartbeat, reduced consciousness, and even death after taking more than 300 mg. If someone takes too much olanzapine, they should be given oxygen, have their stomach emptied, and be given activated charcoal with a laxative. Long-term use of olanzapine has been linked to increased risk of liver and breast tumors and fertility problems in males.

image of a doctor in a lab doing drug, clinical research

Olanzapine Novel Uses: Which Conditions Have a Clinical Trial Featuring Olanzapine?

Presently, 578 active clinical trials are assessing the potential of Olanzapine to remediate Schizophrenia, Post Traumatic Stress Disorder and Delusional Parasitosis.

Condition

Clinical Trials

Trial Phases

Schizophrenia

94 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Post Traumatic Stress Disorder

235 Actively Recruiting

Early Phase 1, Not Applicable, Phase 3, Phase 2, Phase 4, Phase 1

Bipolar Disorder

0 Actively Recruiting

Schizophrenia

30 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Mental Depression

2 Actively Recruiting

Phase 2, Not Applicable

Delirium

22 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1

Unipolar Depression

46 Actively Recruiting

Not Applicable, Early Phase 1, Phase 3, Phase 2, Phase 1

Bipolar Disorder

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Delusional Parasitosis

0 Actively Recruiting

Alzheimer's Disease

37 Actively Recruiting

Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1

Acute Coryza

0 Actively Recruiting

Acute Agitation

0 Actively Recruiting

Tourette Syndrome

0 Actively Recruiting

Olanzapine Reviews: What are patients saying about Olanzapine?

5

Patient Review

2/16/2021

Olanzapine for Schizophrenia

Zyprexa has been a game-changer for me. I've been on it since 2000 and it's helped me immensely. I'm employed, living a good life, and generally happy. If you're struggling, I believe this medication can help certain people. There's hope out there!

5

Patient Review

5/21/2022

Olanzapine for Bipolar Disorder in Remission

As a 16 year old girl who has been taking this medication since she was 5, I can say with certainty that it is incredibly effective in treating bipolar disorder and anger management. I take 20 mg.

3.3

Patient Review

9/10/2022

Olanzapine for Bipolar Disorder in Remission

Olanzipine is effective, but it can cause weight gain and increased appetite at night. I struggled with my weight for a while after starting this medication, but have managed to get it under control by exercising regularly. If you don't want to deal with potential weight gain, I suggest looking into other medications.

2.7

Patient Review

8/7/2022

Olanzapine for Mental Disorder with Loss of Normal Personality & Reality

I gained a lot of weight when taking this medicine and it made me really tired and grouchy. I'm glad I found an alternative a few weeks ago that's helped me lose some weight.

1

Patient Review

10/15/2022

Olanzapine for Manic-Depression

At first, this medication prescribed to me for mania (5mg) was effective. However, it made me very drowsy and I experienced a lot of side effects like weight gain (I went from 78kg to 115kg), almost becoming prediabetic.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about olanzapine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is olanzapine a powerful drug?

"In conclusion, olanzapine may be a more efficacious drug than some other second-generation antipsychotic drugs. However, this small superiority in efficacy needs to be weighed against the risk of larger weight gain and associated metabolic problems than most other second-generation antipsychotic drugs, except clozapine."

Answered by AI

What are the side effects to olanzapine?

"If you experience any of the following symptoms, you should speak with a doctor: dizziness, feeling unsteady, difficulty keeping your balance, restlessness, unusual behavior, depression, difficulty falling asleep or staying asleep, weakness, difficulty walking, constipation."

Answered by AI

Can olanzapine be used for anxiety?

"Olanzapine is often prescribed to target multiple symptoms at once, as it is effective in treating nausea, delirium, anxiety, insomnia, and cachexia. However, it is important to note that olanzapine is a second-generation atypical antipsychotic and as such, palliative care clinicians should be aware of potential side effects."

Answered by AI

What is olanzapine is used for?

"Olanzapine can help relieve symptoms for people with mental health conditions such as schizophrenia and bipolar disorder. These symptoms can include seeing or hearing things that others do not, feeling unusually suspicious, having muddled thoughts, feeling agitated or hyperactive, being very excited or impulsive."

Answered by AI

Clinical Trials for Olanzapine

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of White River Junction VA Hospital in White River Junction, United States.

Transcranial Magnetic Stimulation for PTSD

19 - 70
All Sexes
White River Junction, VT

With this research investigators hope to begin to understand how rTMS can improve posttraumatic stress disorder (PTSD) symptoms. TMS improves PTSD through two interrelated mechanisms: change in brain limbic system function and change in systemic inflammatory activation. Participants who decide to join this study, will receive ten rTMS treatments. All participants will undergo a 40-minute rTMS procedure with a member of the study team 10 times over 2-4 weeks. Participants will undergo fMRI scans of the head in order to help researchers better understand potential effects of rTMS on brain activity. In addition, participants will be asked to give two breath and blood samples to look for signs of general inflammation.

Recruiting
Has No Placebo

White River Junction VA Hospital

Bradley Watts

Have you considered Olanzapine clinical trials?

We made a collection of clinical trials featuring Olanzapine, we think they might fit your search criteria.
Go to Trials
Image of Pavillon Adrien-Pinard (SU) in Montreal, Canada.

Cognitive Remediation for PTSD

18 - 45
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether computer-based brain training can help adults with post-traumatic stress disorder (PTSD). Individuals with PTSD often experience difficulties with memory, attention, concentration, and problem-solving, which can significantly affect their daily lives, work performance, and overall quality of life. These cognitive challenges can hinder trauma recovery and reduce the effectiveness of standard PTSD treatments. The main questions this study seeks to address are: Does specialized brain training improve PTSD symptoms compared to regular computer games? Does brain training enhance cognitive functions such as memory, attention, processing speed, and executive functioning? Does brain training improve quality of life and daily functioning? Do participants' self-efficacy and perceived social support influence treatment outcomes? Researchers will compare two approaches: a specialized cognitive training program (HAPPYneuron Pro) with strategy teachings and quality-of-life discussions, versus engaging computer games with quality-of-life discussions, to determine which is more effective for people with PTSD. Study Design Participants will be randomly assigned to one of two groups for an 8-week program: Cognitive remediation training group: Complete computerized cognitive exercises and strategy teachings specifically designed to strengthen memory, attention, and executive functions, combined with quality-of-life discussions. Control group: Complete engaging computer games combined with quality-of-life discussions. Schedule Both groups will follow the same schedule: One online session per week, in small and consistent groups of 6 participants. Each 60-minute session consists of 30 minutes of computer activities followed by 45 minutes of group discussion. One at-home individual homework exercise per week (30 minutes at home). Total time commitment: 1h45 per week for 8 weeks. Assessments All participants will complete three comprehensive assessment sessions: before treatment, immediately after the 8-week program, and 3 months later. Assessments include neuropsychological testing and questionnaires on PTSD symptoms, depression, anxiety, quality of life, satisfaction with life, social support, cognitive failures, and self-efficacy. Significance This research evaluates a new, accessible and remotely deliverable approach for PTSD treatment. Current evidence-based treatments often do not directly target the cognitive impairments experienced by many individuals with PTSD. Compensation Participants will receive $35 for each completed assessment (maximum $105). Control group participants will gain access to the cognitive remediation training program after completing their participation.

Recruiting
Online Trial

Pavillon Adrien-Pinard (SU)

Have you considered Olanzapine clinical trials?

We made a collection of clinical trials featuring Olanzapine, we think they might fit your search criteria.
Go to Trials
Image of Emory Brain Health Center in Atlanta, United States.

MDMA-Assisted Therapy for PTSD

21 - 70
All Sexes
Atlanta, GA

The goal of this clinical trial is to investigate the efficacy of 3,4-methylenedioxy-methamphetamine hydrochloride (MDMA) combined with Massed Prolonged Exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) in adult participants diagnosed with PTSD. This randomized, placebo-controlled trial will enroll 95 participants. The main questions it aims to answer are: * Does the combination of PE + MDMA lead to greater reduction in PTSD symptom severity from pre-treatment to one-month follow-up compared to PE + placebo? * Does PE + MDMA improve response efficiency and durability of PTSD symptom improvement compared to PE + placebo? * Does MDMA + PE enhance extinction retention and reduce amygdala threat reactivity, and are these changes associated with improved PTSD outcomes? Participants will: * Receive 10 sessions of Massed Prolonged Exposure therapy over two weeks * Be administered either 100 mg of MDMA or a placebo at Visit 2 * Undergo blinded independent evaluator assessments using the Clinician-Administered PTSD Scale for DSM-5-R (CAPS-5-R) at the one-month posttreatment follow-up

Phase 2
Waitlist Available

Emory Brain Health Center

Jessica Maples-Keller, PhD

Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Senseye Diagnostic Tool for Post-Traumatic Stress Disorder

18+
All Sexes
Aurora, CO

The goal of the REVEAL PTSD study is to test how well the Senseye DT works as a diagnostic test for Post-traumatic Stress Disorder (PTSD) in adults 18 and older who are experiencing one or more symptoms that might be related to PTSD. The Senseye DT is software as a medical device (SaMD) and is an iPhone app that administers a series of simple tasks on the phone while recording video during the tasks through the front-facing camera. The videos are analyzed by a a Machine Learning (ML) algorithm to identify physiologic signals that might be indicative of PTSD. Data collected in this study will be used to train and tune the ML algorithm, then test it for accuracy. The main questions this study aims to answer are: 1. How accurate is the Senseye DT in detecting PTSD compared to structured clinical interviews, the current clinical standard for diagnostic testing? 2. How accurately does the Senseye DT predict PTSD severity? 3. How fast is the Senseye DT to use compared to structured clinical interviews? Participants will attend a virtual screening visit via video call to determine eligibility and consent to participate. Once enrolled, participants will attend 2 or 3 additional study visits: * Visit 1: A virtual visit where standard mental health assessments will be given by clinical raters trained in mental health and administering these structured clinical interviews. These assessments include the Structured Interview Guide for the Montgomery-Asburg Depression Rating Scale (SIGMA), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), and the MINI International Neurodiagnostic Interview. The Clinician-Administered PTSD Scale for DSM-5 Revised Version (CAPS-5-R) may also be conducted, if randomly selected. * Visit 2: A visit to use the Senseye DT. For participants near one of the study's physical site locations, this visit will be done in person at the site. For all others, this visit will be conducted virtually. * Visit 3: For participants not randomly selected to have the CAPS-5-R administered at Visit 1, a third and final visit will be scheduled for this assessment. This visit will be conducted virtually. The total expected participation time for enrolled participants is 6-7 hours over the course of 2-3 weeks.

Phase 3
Waitlist Available

University of Colorado Anschutz Medical Campus (+3 Sites)

Senseye, Inc.

Have you considered Olanzapine clinical trials?

We made a collection of clinical trials featuring Olanzapine, we think they might fit your search criteria.
Go to Trials